SCHEMBL31165294

SCHEMBL31165294

C=Cc1ccc(Cn2c3ccccc3c3cc(Nc4ccc(OC)cc4)ccc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX4 Q99571 1/20 0.52
▸ MAPT P10636 8/20 0.48
▸ KDM4E B2RXH2 4/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ HPGD P15428 3/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ LMNA P02545 4/20 0.44
▸ HCRTR1 O43613 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ PAX8 Q06710 1/20 0.44
▸ MAPK1 P28482 2/20 0.43
▸ HTT P42858 1/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31219199 0.81 TP53 (0.54) P2RX4MAPTKDM4ESMN1; SMN2ALDH1A1
SCHEMBL25186625 0.79 MAPT (0.66) MAPTKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL30416772 0.79 MAPT (0.66) MAPTKDM4ESMN1; SMN2ALDH1A1HPGD
SCHEMBL29405472 0.77 CYP19A1 (0.63) P2RX4KDM4EALDH1A1CYP1A2CYP2C19
SCHEMBL30681661 0.77 CYP19A1 (0.63) P2RX4KDM4EALDH1A1CYP1A2CYP2C19
SCHEMBL955942 0.77 CYP19A1 (0.63) P2RX4KDM4EALDH1A1CYP1A2CYP2C19
SCHEMBL18356958 0.77 P2RX4 (0.82) P2RX4MAPTKDM4ESMN1; SMN2ALDH1A1
SCHEMBL30616070 0.77 P2RX4 (0.82) P2RX4MAPTKDM4ESMN1; SMN2ALDH1A1
SCHEMBL17457937 0.76 PSMD14 (0.53) P2RX4MAPTKDM4ELMNAHTT
SCHEMBL31165259 0.76 P2RX4 (0.44) P2RX4MAPTKDM4ESMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240349587-A1 In-Situ crosslinking of 9,9' -spirobifluorene-based compounds for use in optoelectronic and/or in photoelectrochemical devices and manufacture thereof KAUNAS UNIVERSITY OF TECHNOLOGY (LT) 2024-10-17 — — US disclosed
EP-4447643-A1 IN-SITU CROSSLINKING OF 9,9`-SPIROBIFLUORENE-BASED COMPOUNDS FOR USE IN OPTOELECTRONIC AND/OR PHOTOELECTROCHEMICAL DEVICES AND MANUFACTURE THEREOF Kaunas University of Technology (LT) 2024-10-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240349587-A1 In-Situ crosslinking of 9,9' -spirobifluorene-based compounds for use in optoelectronic and/or in photoelectrochemical devices and manufacture thereof INTS9, SLC6A9, SLC19A1 P2RX4 3711/4885MAPT 473/4885KDM4E 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback